Booming Cannabis Consumables Space Continues to see Product Innovations

CannabisNewsWire Editorial Coverage: The North American Marijuana Index of leading cannabis stocks continues to hold onto the 250 range that it meteorically climbed into at the start of the year.

Growing acceptance of cannabis is setting the stage for a consumable cannabis boom.
Major companies have begun to throw their hats into the ring.
North America is steadily headed towards broad legalization.

Canada is legalizing cannabis across the board, Mexico is fast-tracking legalization, and industrial hemp appears to be headed for legalization in the United States thanks to landslide approval in the Senate (86 to 11) of its version of the new hemp-friendly Farm Bill. Prospects of a shift in the reluctant attitude of the House as Democrats prepare to take majority there have also had a positive impact. The global cannabis market is on track to hit $146.4 billion by the end of 2025, and the industry hasn’t even seen the first real breakout commercial product in the fastest-growing CBD (cannabidiol) and beverages/edibles markets. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) is a contender for that recognition with bio-absorption-enhancing technology and a growing line of hemp oil CBD products. GW Pharmaceuticals Plc (NASDAQ: GWPH) continues to be the leading name in cannabinoid prescription medicines with its FDA-approved, oral CBD anti-seizure solution, Epidiolex. WeedMD Inc. (OTCQX: WDDMF) (TSX.V: WMD) ranks as one of the top licensed Canadian producers, with a multichanneled distribution strategy and 70,000 square feet of production space already online. HEXO Corp. (OTC: HYYDF) (TSX: HEXO) is another Canadian producer with a track record for low-cost production that currently has around 310,000 square feet of space with plans to tack on a whopping 1 million square feet by the end of the year. Los Angeles-based MedMen Enterprises, Inc. (OTCQX: MMNFF) (CSE: MMEN) is a rapidly expanding U.S. cannabis company with 19 licensed facilities in four key states representing both cultivation and dispensaries.

To view an infographic of this editorial, click here.

Cannabis-Infused Consumables Primed to Explode

Cannabis-infused beverages saw 88 percent growth in sales from 2016 to 2017, according to analyst Flowhub, and that benchmark is likely to be met or surpassed this year. CBD and the widely known psychoactive cannabinoid THC (tetrahydrocannabinol) are finding their way into alcoholic beverages as decades-old cannabis prohibition slowly retreats ahead of growing consumer confidence about the safety of medical cannabis and recreational marijuana use.

With huge new markets opening up across North America, the potential for cultivators appears to be almost unlimited. Even in places where recreational-use legalization may be a long shot, typically some form of medical access already exists. With baseline metrics such as these, it is little wonder that the North American cannabis market alone was recently projected to hit $41 billion this year, before climbing to $95 billion in 2026.

Bioavailability Tech Could Be Game-Changer

Because of the way the body metabolizes ingested cannabinoids, edibles traditionally are understood to act slowly, taking one to two hours to kick in. Comparatively poorer absorption by the gastrointestinal tract prompts many consumers to pursue more dangerous methods of consumption, such as smoking, in order to achieve the desired effectiveness more rapidly. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed a proprietary lipophilic enhancement technology to bypass this problem, achieving bio-absorption rate increases 10 times greater than other products while slashing the effect onset time from hours to under 20 minutes.

Lexaria’s proprietary technology is patent protected for CBD and other nonpsychoactive cannabinoids and has patents pending for THC, other psychoactive cannabinoids, NSAIDs (non-steroidal anti-inflammatory drugs), nicotine and other molecules. Essentially a B2B, Lexaria is in an enviable position amid the rise of cannabis edibles ranging from recreational drinks to CBD-based nutraceuticals, with a key piece of technology that the company can out-license to third-party partners. Moreover, the company’s proprietary technology may mask undesirable tastes, eliminating the need for sugar-filled edibles, and may actually allow cannabinoids to bypass being broken down by the liver if desired.

Established Presence, Superior Tech—A One-Two Knockout Punch

Lexaria also already has a considerable, established presence in the edibles space, with brands such as the company’s ViPova line of CBD-infused coffee, tea and hot chocolate. The company has seen success since 2014 with beverages such as its original Yunnan Black Tea, which contains 50 mg of Multi Scandinavian full-spectrum hemp oil per serving. These beverages lack the typical oily residue found in most CBD-infused drinks and have virtually no cannabis odor or flavor.

At the low cost of only 2 cents per milligram ($1.25 per serving), the company’s delicious ViPova teas, which come in a variety of flavors including Earl Grey and Herbal Masala Chai, are a testament to Lexaria’s ability to deliver high-value beverages to the cannabis market. The increased bioavailability of the CBD in these beverages, thanks to the company’s proprietary technology, combined with the low per-unit price, represents an incredible value that consumers are noticing. Also, Lexaria’s product mix currently includes the company’s branded Lexaria Energy Foods as well as TurboCBD supplements.

Bottles and Cans Giving Way to Packets of Powder

Capitalizing on its bioavailability-enhancing technology and established presence as a CBD-infused product developer, Lexaria has now moved to tackle the U.S. soft drinks market, which is expected to be worth $388 billion-plus by 2025, introducing a discreet, single-serving foil packet cannabinoid drink powder named ChrgD+. Lexaria is confident that a small two-gram foil packet that can be discreetly carried in a shirt pocket or purse for incorporation into a beverage will be a big hit. After all, consumers can’t show up at their kid’s soccer game with a can of soda whose branding announces “cannabis” to everyone in view.

The multi-spectrum cannabinoid portable drink powder ChrgD+ can turn any drink into a CBD-infused beverage, including wine or cocktails. While currently only available in a CBD-from-hemp version, Lexaria is in talks with cannabis companies to realize its objective of deploying a THC version of the powder.

Powdered single-serving packets of consumers’ favorite drinks have exploded in popularity during recent years as an increasing number of beverage makers are opting to give consumers the convenience of mixing their own drinks from flavor packets containing the rich, distinct flavor profiles of brands they have come to know and love. The same thing is now happening in CBD drinks, and Lexaria may possess some distinct advantages over the competition.

All Kinds of Consumables

CBD and THC appear to be rapidly making their way into all kinds of consumables. The industry’s reputation continues to be improved in the eyes of consumers due to advancing breakthroughs in cannabinoid medicines used to treat everything from epileptic seizures to inflammatory bowel disease.

GW Pharmaceuticals Plc (NASDAQ: GWPH) broke the blockade in cannabinoid medicines with the highly purified, plant-derived CBD indication Epidiolex, which is available in the United States as of November 2018 for the treatment of seizures associated with severe forms of epilepsy. This one company has arguably done more than any other to improve public perception of the cannabis sector, specifically medical cannabis. The company is not resting on its laurels either, following up the availability of Epidiolex via physician prescription with a patient support program designed to help Epidiolex users obtain access to therapy.

WeedMD Inc. (OTCQX: WDDMF) (TSX.V: WMD) moved recently to exploit its position as a leading federally licensed Canadian producer and distributor by executing a pivotal, exclusive development agreement with Montreal-based pharmaceuticals, natural health products and cosmetics developer Smart Medicines GMP. The partnership maps out a comprehensive five-year development plan, including ramping up the operational capabilities of Smart Medicines’ 10,000-square-foot, state-of-the-art Montreal laboratory. WeedMD also recently signed a multiyear retail sales distribution agreement with Lifford Cannabis Solutions, which specializes in helping cannabis companies advance their products through control boards to retail.

HEXO Corp. (OTC: HYYDF) (TSX: HEXO), which produces cannabis through its Hydropothecary brand, issued a major announcement in August that it will develop nonalcoholic, cannabis-infused beverages with Molson Coors Canada. This joint venture with one of the world’s biggest beer makers is a serious play by HEXO to establish itself in the burgeoning cannabis-infused drinks market. This announcement was followed up by word that HEXO has closed on the acquisition of its first major facility outside of Quebec, taking a big step toward realizing the company’s hub-and-spoke business expansion strategy.

MedMen Enterprises, Inc. (OTCQX: MMNFF) (CSE: MMEN) recently signed a definitive $33 million agreement to acquire control of Level Up (Kannaboost Technology and CSI Solutions), which has a 25,000-square-foot production facility as well as retail locations in Scottsdale and Tempe, Ariz. Furthermore, MedMen will obtain a 40 percent stake in the top-selling K.I.N.D. Concentrates brand via the acquisition. MedMen also recently acquired the retail operations and license for a key location in Santa Ana, California, from Captor Capital Corp. in an all-stock transaction, adding to the company’s growing strategic footprint in one of the most affluent areas of Southern California.

With several of the world’s largest beverage makers on the fence about entrance into the CBD-infused beverages market, the stage is set for smaller players, as well as majors from parallel sectors without a significant ground game in nonalcoholic drinks. But beverages are just one aspect of a rapidly evolving industry that spans the gamut from edibles and concentrates to grow-ops and biopharma development.

For more information on Lexaria Bioscience Corp., visit Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Growing Cannabis Industry Creates Space for New Strategies

CannabisNewsWire Editorial Coverage: As the cannabis industry continues to grow, companies are using a variety of strategies to secure their places within the sector.

The cannabis sector, currently worth over $9 billion in North America, is expected to hit $57 billion globally by 2027.
This growth is being fueled by changes in the legal climate and a range of business strategies.
These strategies range from R&D focus to M&A, vertically integrating supply channels in the process.

Youngevity International, Inc. (NASDAQ: YGYI) (YGYI Profile), a relative newcomer to the sector, is bringing its vertically integrated strategy from the coffee market to cannabis. GW Pharmaceuticals Plc (NASDAQ: GWPH) is focused on the medical market, developing prescription medicines among other products. Charlotte’s Web Holdings, Inc. (OTCQX: CWBHF) (CSE: CWEB) is focused on reaching more retail outlets, pushing its CBD products out through a growing number of channels. CV Sciences, Inc. (OTCQB: CVSI) is primarily research oriented but is also raising its profile through sponsorship of a hemp industry conference. In Canada, Aurora Cannabis, Inc. (NYSE: ACB) (TSX: ACB) is making use of recent changes by establishing a range of new supply agreements.

To view an infographic of this editorial, click here.

A Changing Business

This year has seen huge developments for the cannabis industry in North America. In Canada, recreational cannabis became legal in the middle of October, after a year of political debate and commercial preparation. South of the border, pressure mounted for reform of federal laws to support states making their own choices, with 64 percent of Americans now saying that they favor legalization. While political maneuvering ahead of the midterm elections delayed efforts to legalize industrial hemp through the 2018 Farm Bill, voters supported the legalization of medical cannabis in Missouri and Utah and of recreational cannabis in Michigan. With cannabis now legal for medical use in 33 states and for recreational use in 10, prohibition is clearly on its last legs.

This wave of change is leading to staggering growth in the cannabis industry. Companies are seeing dramatic rises in revenue as new markets open up, new products are created and new customers cast off tradition to give cannabis a go. This is creating a new space for cannabis companies to work in, where new strategies are being tested alongside new products.

Cannabis Market Keeps Growing

For companies such as Youngevity International, Inc. (NASDAQ: YGYI) that have a significant investment in cannabis, the past few years have been promising ones. The cannabis market has steadily grown as popular sentiment-driven legalization has opened the way for companies to thrive, which in turn has strengthened their campaigns for further legalization. The success of first medical and then recreational legalization in many states and Canada has reassured others that this is a safe path to follow, creating a North American industry that was worth over $9 billion in 2017, according to a Forbes report. That value is forecast to keep rising, with a predicted value of $47.3 billion by 2027.

With notable exceptions such as Uruguay and Israel, the rest of the world has been slower to follow, but that too is changing. Germany permitted the sale of medical cannabis through pharmacies in 2017. Even Britain, one of Europe’s most conservative countries, opened the door to doctors prescribing cannabis products this year after a high-profile campaign by the mother of an epileptic child. Taken all together, the global market is expected to be worth $57 billion by 2027, according to the Forbes report.

A significant part of that industry is made up of cannabidiol (CBD) products. Derived from both marijuana and industrial hemp, CBD is used in health and wellness products such as Youngevity’s Hemp FX™ range. Though some industry predictions may be unreasonably optimistic, performance indicates that CBD products are increasingly popular and are expected to give a significant boost to cannabis businesses. With Congress expected to legalize widespread hemp cultivation as part of the current Farm Bill, the supply of CBD has the potential to soar.

Developing New Strategies

In the early days of the cannabis industry, corporate strategy was simple. Produce the best cannabis possible, market it within the limited options regulations allowed, and soak up the demand from customers. Now the industry is a more diverse one, from focused pharmaceutical brands to the likes of Youngevity, which combines an interest in CBD with other lifestyle products. Strategies have evolved to match the changing market.

One common path has been that of mergers and acquisitions. In a market full of small businesses, there’s plenty of potential for the big movers to swallow up competitors. This has really taken off in 2018, a year that saw 145 mergers and acquisitions during its first six months, compared with 79 M&As in the first half of 2017.

Investment by and in cannabis companies has also increased. From Sugarmade’s investment of a million dollars in Hempistry to Constellation Brand’s decision to pump billions into Canopy Growth, companies are investing in each other to profit from different parts of the market or to easily enter it for the first time.

For others, product diversification is a common way forward. As the market grows, so does the ingenuity of the companies involved. R&D departments are producing an increasingly wide range of products, whether strains of cannabis or derivatives using CBD. Youngevity has recently added sleep and hydration products to its existing range, as the company finds more uses for CBD and more corners of the market to expand into. The spread of legalization is making it easier for companies to carry out this R&D work, leading to ongoing acceleration in the number of products coming out.

Vertical Integration

While some companies are focusing on horizontal integration, absorbing potential competitors in the same part of the cannabis business, others are looking at vertical integration.

This is the approach taken by Youngevity, with a strategy it refers to as “field to finish.” This is an adaptation of the “field-to-cup” strategy the company takes with coffee, seeking to control the whole supply chain, from the cultivation of beans through to the moment the coffee is delivered to the customer. Except that this product is cannabis instead of coffee.

The field-to-finish strategy offers many advantages for a company that can achieve it. By controlling cultivation, processing and distribution, it can ensure high-quality standards, an important part of Youngevity’s lifestyle brand. It can also benefit from the efficiencies and improved communication that come with an integrated supply chain. Many of the blockages that introduce inefficiencies are more easily removed in a system such as this, leading to a leaner, more cost-effective operation.

Youngevity has only recently entered the CBD market, but the company has grand plans. “We firmly believe in plant-based nutrition, and hemp (CBD) oil perfectly complements our product development philosophy,” said Steve Wallach, the company’s CEO. “Entering this market, which is growing almost exponentially, also should offer a tremendous advantage to our many distributors around the world.”

As Wallach has repeatedly made clear, the products so far released are only the beginning for Youngevity.

Players Big and Small

With the market going through dramatic changes, both large and small companies are making significant moves to expand their slice of the pie.

GW Pharmaceuticals Plc (NASDAQ: GWPH) has built a strategy strongly oriented towards the medical market. This includes not just selling strains of cannabis but creating other medicines based on it. The company has created the first plant-derived cannabinoid medicine to gain U.S Food and Drug Administration approval, getting GW’s products into the prescription drug market across the United States. By creating new and valuable medicines, it is creating a place as a prestigious innovator with customers’ wellbeing at its heart.

Charlotte’s Web Holdings, Inc. (OTCQX: CWBHF) (CSE: CWEB) is catering to the broader health and wellness market with its CBD-based products. As mainstream acceptance of CBD grows, the company is expanding into a wider range of stores and has now reached 3,000 outlets.

Like GW, CV Sciences, Inc. (OTCQB: CVSI) has built its business around research, using its expertise to create new products and to sell its services to consumers. CV Sciences was the first hemp CBD nutraceutical company whose products were certified Generally Recognized as Safe (GRAS) by the FDA, helping improve the image of both the products and the cannabis market. The company is further raising its profile within the industry as a sponsor of HIACON 2018, the Hemp Industries Association’s 25th anniversary convention.

For Canadian companies such as Aurora Cannabis, Inc. (NYSE: ACB) (TSX: ACB), recreational legalization has opened up a whole new market that presents new opportunities and new challenges. With the market regulated province by province, companies have to set up supply agreements to cover different regions. Aurora has been busily setting up these agreements, giving it a wide distribution network over an important new market.

The expansion of the cannabis market has led to a range of strategies, from acquisitions and product development to opening up new distribution channels, leading to growth for a diversity of different companies. The next few years will show which strategies work best.

For more information on Youngevity, visit Youngevity International, Inc. (NASDAQ: YGYI)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Payment Solutions Among Innovations in the Fast-Growing Cannabis Industry

CannabisNewsWire Editorial Coverage: The legal cannabis industry, which anticipates massive growth over the next few years, is seeing constant innovation as companies move to provide essential services needed for that growth.

The global cannabis industry, which was worth $7.7 billion in 2016, is expected to reach $65 billion by 2023.
The industry’s upward trajectory is happening despite legal restrictions that have forced cannabis businesses to seek alternative payment solutions.
These solutions are among many innovations in the sector, which has a strong strand of research and design.

Net Element (NASDAQ: NETE) (NETE Profile) recently launched a compliant, secure payment processing solution focused on serving the legal cannabis industry. Medical cannabis company Tilray, Inc. (NASDAQ: TLRY) is supplying materials for a range of research projects around the world that are studying cannabis’ potential in medicine. Canopy Growth Corporation (NYSE: CGC) (TSX: WEED) has received massive investment from a beverage company and is likely to be one of the first companies selling cannabis-infused drinks. And the first U.S. Food and Drug Administration (FDA)-approved cannabis-based drug has just gone on sale from GW Pharmaceuticals Plc (NASDAQ: GWPH). Meanwhile, new uses for the plant are being found, as exemplified by Cronos Group, Inc.’s (NASDAQ: CRON) (TSX: CRON) research on the use of cannabis in skin cream.

To view an infographic of this editorial, click here.

Cannabis Payment Solutions

The cannabis industry is currently growing at an astonishing rate. Since 1996, its use for medical purposes has become legal in 31 U.S. states and Canada as well as a number of other countries around the world, most recently the United Kingdom. This remarkable pace of change has been accompanied by the emergence of related industries producing industrial hemp, cannabidiol (CBD) oil and support services for cannabis growers.

Despite this, legal cannabis sellers in the United States face serious problems in accessing basic business services. Because banks and payment providers are often wary of working with cannabis companies — even legal ones — these companies are forced to either accept the risks and inefficiencies of a cash-based business or seek alternative payment options. Fortunately, payment solutions are becoming increasingly viable.

The Challenge — And Opportunity

The challenge — and opportunity — with cannabis payment processing is significant enough to have drawn in businesses from outside the sector, such as global technology company Net Element (NASDAQ: NETE).

With the growth of the medical cannabis market has come more people are looking for one of the sectors most in-demand products — CBD oil, which is the concentrated liquid extract of the cannabis plant. Previously most CBD products were sold in head shops, but increasingly these products are found on the shelves of natural food stores, beauty aisles, cafes and doctors’ offices. This spread to other venues has created an even greater need for smooth transactions between merchants and consumers.

While the majority of states now allow the legal sale of some form of cannabis or its derivatives within their boundaries, cannabis providers may still find it challenging to find payment options that allow mobile payments, offer value-added transactions, and are easy for both the business and the end user. Fortunately, companies such as Net Element are positioning themselves to provide exactly what this underserved industry is looking for.

These alternative solutions, including Net Element’s Aptito and Unified Payments systems, solve the problem by offering a compliant, seamlessly integrated payment solution that is simple to use. The systems rely on the latest digital technology, which allows retailers to accept payments outside of conventional routes while remaining user friendly for customers.

More Sales, More Payments

It’s a good time for companies to expand their reach in the cannabis market, as Net Element is doing. The industry is experiencing a period of huge growth. According to recent research, the legal cannabis market was worth $7.7 billion in 2016 and is forecast to reach $65 billion by 2023, a staggering 37 percent rate of compound growth per year.

Various factors are playing into this. Cannabis is already a huge industry, but one historically run by criminal gangs. One of the reasons for wide legalization is to take that trade out of criminals’ hands. In the United States, 70 to 75 percent of the cannabis trade is still illegal, but only 30 percent of it is illicit in states with legal options on the books. As legal cannabis from regulated suppliers becomes more widely available, the expectation is customers will move away from illegal businesses. The customer base is already there, and it’s huge.

Ongoing changes in the legal landscape are also a factor. The White House has hinted that it is considering liberalizing federal cannabis laws. Shifts in medical-use cannabis are taking place in Germany and the United Kingdom. In the United States, the current Farm Bill has enough support that it is expected to legalize the widespread cultivation of industrial hemp for nonrecreational cannabis uses.

This last change ties into an unexpected and significant trend in the cannabis industry. Hemp, a nonpsychoactive form of cannabis, was used in manufacturing rope and cloth before being made illegal during the political campaign against marijuana. Now, it’s returning to legality as a source of a new material — CBD oil. This active ingredient of cannabis is used in a growing number of health and well-being products. The hemp and CBD parts of the industry alone are set to reach $22 billion by 2022. While CBD sales are still largest in the stores supported by companies such as Net Element, these products are moving towards the mainstream via health stores, beauty aisles and cafés.

Rising to the Problem

A growing sector with a need for innovative solutions is the perfect place for a company such as Net Element to act on its vision.

“We are excited to launch a legal cannabis payment acceptance solution to meet the needs of sales partners and merchants for this emerging market,” commented Vlad Sadovskiy, president of integrated payments for Net Element. “Addressing the needs of our merchants is our number one priority and we work closely with various vendors to bring our merchants state-of-the-art payment acceptance solutions.”

The cannabis sector is more than just cultivators and retailers. It also includes the companies that support those businesses, companies that are set to thrive if the industry maintains its spectacular growth. The industry’s circumstances have ensured that it has become a forward-looking one.

A Future-facing Industry

Cannabis companies constantly have an eye on the state of the legal landscape and the new opportunities it may create for the market. Because those companies are working in an industry that has been illegal, industry-building techniques and products are only beginning to be properly discussed now, with innovations in research and design being announced as a result. Constraints such as those established by the U.S. government are forcing them to find technological solutions to problems other companies don’t face.

Medical cannabis company Tilray, Inc. (NASDAQ: TLRY) prides itself on the part it plays in pushing the industry forward. With a strong emphasis on industry and innovation, Tilray is committed to research that will expand the possibilities of cannabis, carried out in partnership with hospitals and universities. It is currently supplying products for a range of clinical trials in Australia and Canada that promote the safety and effectiveness of cannabis use in tackling ailments such as childhood epilepsy and chemotherapy-induced nausea.

Research and design work at Canopy Growth Corporation (NYSE: CGC) (TSX: WEED) has been super-charged by a recent investment of billions of dollars from American drinks company Constellation Brands. One of the reasons for Constellation’s move into cannabis is the potential for drinks infused with cannabis and CBD. The partnership with Canopy Growth is likely to lead to novel products that will become part of Canada’s large licensed cannabis market next year.

GW Pharmaceuticals Plc (NASDAQ: GWPH), a company with a strong history of research in the cannabis sector, has created the first plant-derived cannabinoid medicine to be approved by the FDA, which has just become available by prescription in the United States. This introduction of a federally approved cannabis-derived medicine is an important moment for the industry and may lead to the softening of political and regulatory attitudes that have previously held business back.

Cronos Group, Inc. (NASDAQ: CRON) (TSX: CRON) is investigating the use of cannabis in a relatively new area – skin care. The company has announced that it will be working with the Technion–Israel Institute of Technology to research the use of cannabinoids in skin care, research with potential to carry cannabis into more parts of the high street and the consciousness of more consumers.

From payment solutions to new products, the cannabis sector’s growth is fueling a rich wave of innovation.

For more information on Net Element, visit Net Element (NASDAQ: NETE)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Cannabis Ignores Wider Stock Market, Follows Its Own Path

CannabisNewsWire Editorial Coverage: Following a tumultuous month, cannabis continues to carve its own path rather than following the lead of other stocks.

As the stock market plummeted earlier this month, cannabis companies stayed strong, buoyed up by legislative changes in Canada.
The cannabis market appears set for continuing growth as it expands into expected sales worth billions of dollars across North America.
While it still faces regulatory challenges in some locations, this market sector is preparing for corporate big players to move in.

Companies with varied interests are moving into the cannabis sector, such as lifestyle business Youngevity International, Inc. (NASDAQ: YGYI) (YGYI Profile). While the stocks of some cannabis players such as Tilray, Inc. (NASDAQ: TLRY) appear overvalued, this reflects problems with valuation tools more than the stocks themselves. The sector has developed its own heavy hitters, such as Canopy Growth Corp. (NYSE: CGC) (TSX: WEED), whose millions of square feet of growing space are now leading to sales into the United States as well as Canada. Some companies are focused only on medical products, such as GW Pharmaceuticals Plc (NASDAQ: GWPH) with its cannabis-based prescription medicines. But it’s the recreational side of the cannabis space that has drawn in Constellation Brands Inc. (NYSE: STZ), a huge beverage maker that has invested $4 billion in a cannabis cultivator.

To view an infographic of this editorial, click here.

Cannabis Stocks Versus the Market

It’s been an interesting month for cannabis stocks.

Three weeks ago, cannabis looked like a particularly strong bet. As the wider stock market fell, cannabis stayed strong. Some cannabis stocks even saw significant rises in value amid promising developments from those companies. Legalization in Canada undoubtedly played a part in their success, with the run-up to Oct. 17 seeing predictions of massive profits for cannabis companies. But some commentators argued that it was part of a bigger trend in which cannabis stocks are among those that don’t follow other market indicators.

Then came the week following legalization and a notable fall in the value of cannabis shares. The hype around these companies was punctured by market shifts. Had they fallen in line with the rest of the market? Was the reality of Canadian legalization catching up with the imagined utopia? Or was this simply a downturn for a sector trending separately from competitors?

More to the Market

To understand shifts in cannabis shares, one needs to take a look at the state of the industry.

The cannabis industry isn’t self-contained. The spread of legalization and the emergence of derivative products has created a diverse sector combining exciting startups with older companies dipping their toes in a novel market. Alongside the pure-play cannabis brands, there are pharmaceutical businesses and even lifestyle companies such as Youngevity International, Inc. (NASDAQ: YGYI).

These companies are selling three distinct products.

First, there’s medical cannabis. Supplied on prescription to deal with pain and nausea, cannabis’ medical properties remain hotly debated but that hasn’t stopped the state-legalized use of it from spreading across more than half of the United States.

In material terms, recreational cannabis has exactly the same chemical makeup as some of the medicinal products. What’s primarily different is the way that it’s marketed, sold and used. This is cannabis used for fun and relaxation. It’s now available by law in nine U.S. states and Canada.

Then there are the derivative products. Most, including those sold by Youngevity, use cannabidiol (CBD). Cannabidiol is an active ingredient that doesn’t get users high. CBD can be extracted from cannabis, both from the marijuana plant as well as its tetrahydrocannabinol (THC)-free variety known as industrial hemp. Research into CBD is still in its infancy, but it is already used in a wide range of health and wellness products.

Over the past 20 years, cannabis has grown from a black market drug to a major public market product in North America, with growing influence in the rest of the world. From the first stirrings of a medical market to the current state of affairs in which a G8 country has a recreational market and the White House is hinting at U.S. reforms, it’s been a fast ride. As a result, there’s still a lot of uncertainty about cannabis’ destiny.

Where Now for Cannabis Shares?

The idea that weed doesn’t correlate to other stocks seems to have some truth. This was shown by the events of early to mid-October, when legal reform and individual brand announcements set it on an opposite trend from other shares. While the Dow has headed towards its worst month since May 2010, cannabis stocks have carved their own path. It looked like good news for companies such as Youngevity.

For now, cannabis is offering a real challenge for traders. Cannabis stocks look overvalued based on traditional valuation metrics such as price-to-book ratio, price-to-earnings ratio or price-to-sales ratio. But these metrics are based on past results, not future valuations. Given ongoing changes, the future performance of cannabis companies will be nothing like the past. Whole new customer bases are opening up, bringing staggering potential for growth.

In the next month, there will be votes on whether to allow recreational cannabis in North Dakota and Michigan, at least one of which is likely to pass. North of the border, Canada is planning to legalize cannabis-infused edibles next year. That means a whole new sector of profit opportunities.

Then there’s the impending arrival of big players in the market. Big pharmaceutical and consumables companies haven’t paid much attention to cannabis yet, as its value is relatively low compared with their existing revenues. But with the market expanding, both groups may get involved — beverage and tobacco companies pursuing a natural spin-off from their existing businesses and big pharma in pursuit of new medicines. Those are moves that will bring disruption unrelated to wider markets.

As a lifestyle brand selling both coffee and cannabis derivatives, Youngevity has already placed itself to enter this cross-over market. And with its new HempFX™ line now available online, it’s moving fast to profit from changes in the cannabis market.

Riding High

Alongside medical and recreational marijuana, CBD is seeing huge growth. Youngevity CEO Steve Wallach has spoken about the huge potential of CBD products in direct sales channels, not just in America but around the world. His company is riding high on this trend with the announcement of new CBD products.

Youngevity’s first offering in the CB market is the HempFX™ product line, a trio of three different hemp-derived cannabidiol oil products that contain organically grown products in proprietary formulas designed for a variety of everyday use.

The products include Soothe™, a blend of botanicals designed to relieve muscles by calming aches and pains; Uplift™, which combines CBD with St. John’s Wort to improve cognitive performance and mood; and Relax™, which combines CBD with a variety of herbs and melatonin to bring relaxation and a better night’s sleep.

Cannabis’ Long-Term Prospects

The signs remain good for cannabis companies. One study predicts that sales in Canada could reach $7.1 billion in 2019, $4.3 billion of that coming from the recreational market.

The boss of cannabis company Tilray, Inc. (NASDAQ: TLRY) believes that the market in the United States will soon be worth $150 billion. A leading player in the medical cannabis market, Tilray has established agreements with Canadian partners that will let it profit from changes in that country, changes that could radically improve its earnings.

Other companies are also making significant movements in the market. Drinks giant Constellation Brands, Inc. (NYSE: STZ) has invested $4 billion in Canopy Growth Corp. (NYSE: CGC) (TSX: WEED), showing that it is serious about moving into the cannabis market. Canopy Growth is one of Canada’s largest cannabis companies, with 5.6 million square feet of growing space. Like Tilray, it’s looking at the wider North American picture and carried out a legal transfer of cannabis to the United States, the first such transfer with a Drug Enforcement Administration (DEA)-issued permit.

Canopy Growth’s strong performance has drawn the attention of companies outside the cannabis sector, leading to the headline-making investment from Constellation Brands earlier this year. Many commentators have talked about this as a chance for Constellation to produce cannabis-infused beverages, a largely untapped market likely to take off once new rules come in Canada next year. But it may represent a broader play, as alcohol and tobacco companies aim to take control of cannabis and fill the gaps as sales of their existing lines fall.

Some companies are focused only on the medical market. GW Pharmaceuticals Plc (NASDAQ: GWPH) has created the first Food and Drug Administration (FDA)-approved cannabis-based prescription medicine as part of its substantial research and design program. Even as the recreational market and CBD steal its thunder, the medical market remains strong.

Clearly, there are still big uncertainties for the cannabis market. Questions about regulation and how far legalization will spread hang over everybody’s heads. Yet companies are thriving despite this, showing the rewards that so often come with risk and innovation.

For more information on Youngevity, visit Youngevity International, Inc. (NASDAQ: YGYI)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Flow of Finance Funds Acquisitions and Investment Across the Cannabis Sector

CannabisNewsWire Editorial Coverage: A growing market is supporting a wave of acquisitions and cross-company investments in the cannabis industry.

Significant growth in the cannabis industry is supporting a range of multimillion-dollar investments.
Some of these have taken the form of acquisitions, as innovators evolve into established companies.
Others are cross-company investments, some within the sector and some from outside.
Profits are coming not just from cannabis itself but from support services, with companies profiting from pick-and-shovel plays.

One of the companies making a pick-and-shovel play is Sugarmade, Inc. (OTCQB: SGMD) (SGMD Profile), which is expanding its position in cultivation supplies through acquisitions and marketing agreements. GW Pharmaceuticals Plc (NASDAQ: GWPH) recently carried out a public offering to fund further growth, raising $345 million to expand its cannabis-oriented pharmaceuticals work. AbbVie, Inc. (NYSE: ABBV), on the other hand, has retained only a limited connection to cannabis, moving instead into other treatments. Specialist consulting company MariMed, Inc. (OTCQB: MRMD) provides advice for those looking to expand in the sector, covering the development and management of cultivation facilities, and recently investing in a related software company. For Medmen Enterprises, Inc. (OTCQX: MMNFF) (CSE: MMEN), expansion means a vertically integrated supply chain across four US states as it expands a carefully developed brand.

Cannabis Acquisitions Continue as Companies Seek Liquidity

With the completion of cannabis legalization in Canada, investors are watching closely to see what effect this will have on the market. Over less than 20 years, cannabis has evolved from nothing into a multimillion-dollar industry, with companies ranging from cultivators and retailers to payment specialists and equipment suppliers. As it continues to expand at a rapid rate in both Canada and the US, the market is seeing growth for players both big and small.

To fuel this development, many companies are looking for fresh finance. Liquidity is needed to fund research, development, and expansion, from building larger cultivation facilities to setting up new retail outlets. This is both driven by and driving a wave of new finance deals and acquisitions, as the sector matures and consolidates its resources.

Acquiring the Fundamentals

The appeal of acquisitions is driving the strategy of companies such as hydroponics supplier Sugarmade, Inc. (OTCQB: SGMD). Hydroponic equipment is essential to the indoor cultivation of cannabis, so the growth of the sector promises a boom in demand for hydroponics. Sugarmade is using this boom to attract additional finance and undertake a raft of acquisitions, with an end goal of becoming a major player not just in hydroponics but in the cannabis space itself.

Such acquisitions have taken off in a big way over the past year. The first half of 2018 saw 145 mergers and acquisitions in the cannabis sector, nearly double the number for the same period in 2017. Some of these represent consolidation by existing cannabis players, as they mature from innovative startups into established businesses in a widely accepted field. But money is also coming in from the outside, for example through Constellation Brands’ acquisition of a large portion of Canopy Growth.

A pattern is emerging of cannabis-adjacent companies moving directly into the sector. For a company such as Constellation, the move is a sideways one from investment in alcohol to one in cannabis, protecting its place in the recreational consumables market. It’s the same play that other alcohol and tobacco companies are eyeing. For Sugarmade, acquisitions represent expansion within its existing business, ensuring a firm hold on hydroponics, as well as a move up and down the supply chain to better profit from the businesses it is already tied to.

A Pick-and-Shovel Strategy

Earlier this year, Sugarmade announced that it was moving to acquire two other suppliers of cultivation equipment. Now details of those deals are emerging, with the signing of a binding Letter of Intent (“LOI”) to acquire Sky Unlimited, LLC. This could allow Sugarmade to expand its distribution channels, thanks to the different models followed by the two companies. While Sugarmade’s sales to the cannabis sector primarily come through online buyers, Sky Unlimited specializes in selling to wholesalers and large commercial cultivators. Combining the two may create manufacturing, logistical, and marketing efficiencies across an expanded customer base.

“The trend in cannabis cultivation is toward the larger commercial cultivation operations, and Sky Unlimited is in the thick of that dynamic marketplace,” said Jimmy Chan, CEO of Sugarmade. “This year, Sky Unlimited and its associated operations are expected to produce in excess of $40 million in revenues with profitability and positive cash flow. This new revenue stream combined with our recently upwardly guided revenue forecast of $30 million for next year will make Sugarmade one of the largest publicly traded suppliers to the booming cannabis cultivation marketplace, with a combined revenue forecast for next year in excess of $70 million.”

The types of company being targeted by Sugarmade reveal a pick-and-shovel strategy. Rather than making a direct jump into cannabis, the company is investing in the underlying products and services cannabis suppliers need. It’s a more conservative move than investing directly in cannabis, one that will buffer Sugarmade against the immediate effects of a fast-changing and still controversial sector, while letting it profit from the sector’s growth.

Following a previous Master Marketing Agreement with BizRight, this latest move makes Sugarmade one of the largest publicly traded cannabis supply companies. The company shows no sign of stopping there, having announced its intention to continue with an expansion strategy. The next likely move may well be brand acquisition, providing a higher price-to-earnings ratio for investors. Having already made an acquisition proposal for a Washington state retailer with $5 million in annual revenues, Sugarmade is on its way to becoming a more public fixture in the cannabis market.

Financing Growth in Cannabis

As in any sector, the success of expansion strategies will depend upon their liquidity. Fortunately, the state of the cannabis market appears to currently ensure a steady stream of finance. The US cannabis market alone is expected to be worth $10 billion in 2018, 50 percent more than it was only two years ago. Canada’s market is also expected to be worth billions, as legalization transfers the recreational consumer base from illegal dealers to legitimate businesses.

Cannabis companies are using this opportunity to channel finance into growth. Some are striking deals for bank loans in newly legalized regions, while others are using public offerings to raise fresh finance through sales of shares.

Sugarmade is taking a different approach, using expansion to fund further expansion. Following the BizRight and Sky Unlimited deals, the company has upgraded its projections for revenue in 2019 from $6 million to $70 million. Its previous deals will now provide the liquidity for future acquisitions, allowing a rolling strategy of expansion across the sector.

The pick-and-shovel plays look to pay off.

Cannabis Companies Making Big Moves

As the market keeps growing, so do many of the companies working in cannabis.

GW Pharmaceuticals Plc (NASDAQ: GWPH) is a world leader in the development of cannabis-related medicines, thanks to its strong research program and manufacturing expertise. Already a major player in the sector, the company has recently sought funds for expansion through a public offering. The result was an extra $345 million in funds, reflecting investors’ faith in the cannabis sector and in the future of companies such as GW. These funding will allow the company to keep growing its research and production work, with that research work expanding its portfolio of cannabis-related intellectual property.

While some companies invest more heavily in cannabis, others are diversifying. Pharmaceuticals manufacturer AbbVie, Inc. (NYSE: ABBV) is the company behind Marinol, a drug used to tackle appetite loss due to AIDS and cancer treatments. But while Marinol’s active ingredient is chemically identical to THC, the best-known active ingredient in cannabis, the company has filed only a handful of patents relating to cannabis and shows no sign of expansion into the sector. It’s a move that may help AbbVie in marketing to cannabis’s opponents, but one that leaves the space open for competitors.

The expansion of cannabis companies has supported the emergence of specialist support services, such as those provided by MariMed, Inc. (OTCQB: MRMD). A cannabis consulting firm, MariMed provides professional guidance on the development, funding, and operation of cultivation facilities. This can help other firms navigate the complicated issues surrounding the industry, covering everything from real estate to regulatory compliance. The company recently invested in Sprout, a software company supporting cannabis brands and dispensaries, allowing it to bundle software with its other business solutions.

Medmen Enterprises, Inc. (OTCQX: MMNFF) (CSE: MMEN), has used expansion to develop a vertically integrated supply chain. The company works in both cultivation and retail, meaning that it handles the product all the way from planting first seedlings to placing packaged cannabis into customers’ hands. Its recent acquisition of dispensary and cultivation facilities from Treadwell Simpson Partnership means that it is spreading its carefully managed brand from existing bases in California, Nevada, and New York into Florida.

The growth of the cannabis market is providing a flow of finance, leading to acquisitions and cross-company investments across the sector.

For more information on Sugarmade, visit Sugarmade, Inc. (OTCQB: SGMD)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Canada Leads International Cannabis Boom — and It’s Not About Smoking

CannabisNewsWire Editorial Coverage: Legal changes in Canada are creating an ideal base for cannabis companies, which are shifting their focus away from smoking.

As the first G20 nation to make recreational cannabis legal, Canada is creating an opportunity for its cannabis companies to become global leaders.
Analysis shows that the global cannabis market is larger than expected — and set to keep growing.
Many new consumers prefer not to smoke their cannabis, leading to a shift towards cannabis-derived food and drinks.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has developed patented technology that helps make cannabis available to nonsmokers; the company’s innovative development methods make cannabis’ active chemicals more palatable and more effective in food and drink. Companies such as Tilray, Inc. (NASDAQ: TLRY) are expanding their production to cater to this growing market, resulting in rising share values. GW Pharmaceuticals Plc (NASDAQ: GWPH) has leveraged its position in the market to raise extra financing through a $345 million public offering. Aurora Cannabis, Inc. (OTC: ACBFF) (TSX: ACB) has been focusing on ensuring access to a broad market, setting up supply agreements across Canada. Meanwhile, other companies are evaluating international growth opportunities, with Cronos Group, Inc. (NASDAQ: CRON) (TSX: CRON) having established subsidiaries on five continents.

The Canada-led Revolution

This month marks one of the most dramatic changes ever in the cannabis market, a moment set to transform the industry and the way that it’s viewed. As of Oct. 17, consumers across Canada are able to buy cannabis for recreational consumption for the first time. Canada is the first G20 nation to make such a change, and the precedent could be critical. Other countries are watching what happens in Canada, as voters around the world push their governments toward similar legalization; there are already more than 30 countries around the world where cannabis is legal in some form for medical use.

The Canadian example comes just as analysis shows that the cannabis market is larger than previously realized and set for continued growth. This puts Canadian companies in a powerful position, able to make the most of being based in a country that’s friendly to the cannabis industry. By using the freedom and opportunities this presents, these companies could easily become global leaders in a fast-growing sector.

Canada Legalizes Cannabis

For Canadian companies working in the cannabis sector, such as Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), huge changes are coming.

After much political maneuvering, recreational cannabis is now legal in Canada in keeping with a promise made by Justin Trudeau when he was elected prime minister in 2015. The wait has been frustrating for some, but it has given companies such as Lexaria time to establish their leadership position.

Canada already has a thriving medical cannabis industry, in which tight regulation provides control over the use of drugs. The new regulations extend this careful approach to the recreational market. Using a model similar to liquor licensing, retailers will have to be licensed to sell cannabis and follow clear rules. Those who try to sell outside the system will be quickly shut down.

In setting up its system, the Canadian government and provincial authorities have learned from the example of legalization in certain U.S. states. They worked with cannabis companies to ensure that the licensing system for both production and retail was ready for the Oct. 17 deadline While there will undoubtedly be hitches, including the likelihood that demand will initially outstrip supply, this appears likely to be a smooth launch.

Companies have also been making adjustments. For example, Lexaria recently announced a new subsidiary, Lexaria CanPharm Corp., which is focused purely on applying the company’s technology to the cannabis industry. Because Lexaria sells technology, if is already earning revenue in several locations both within and outside of Canada without touching the plant. Lexaria has a Canadian base but international reach.

Cannabis Market Larger Than Expected

Judging the potential size of the legal cannabis market is a tricky business. The drug’s widespread illegality around the world means that data is almost entirely drawn from surveys, in which respondents may be wary of admitting their consumption. Legalization will likely lead to changes in consumption patterns; easier access will almost certainly increase both medical and recreational demand.

Despite the limitations on judging the market, observers have been keen to estimate what the market could represent. A survey from before legalization indicated that 4.2 million Canadians consume cannabis on a regular or occasional basis. Based on this data, companies and commentators have predicted an industry worth billions of dollars, which could quickly surpass the whiskey industry.

But leading cannabis commentators are now suggesting that previous estimates may have undervalued cannabis’ potential. The only specialist cannabis analyst for a major Wall Street trading firm believes that the impact of legalizing a previously illegal market has been underestimated. Legalization could lead not just to large-scale sales of cannabis but also to its use as an ingredient in other products. Because Fortune 500-type companies are now interested in the space, the market could eventually be worth hundreds of billions of dollars.

If that analysis is accurate, then many cannabis companies are being massively undervalued. That’s good news for the future prospects of businesses such as Lexaria.

Consuming Cannabis without Smoking

This growth is likely to be coupled with changes in the way cannabis is consumed — changes of huge relevance for Lexaria.

A recent survey of U.S. consumers showed that many would like to try cannabis if it became legal. They also said that they would be more likely to do so if they could consume the plant through food. Putting cannabis into drinks and snack foods will make it easier for people to enjoy in a social setting with friends, in a similar way that they currently consume alcohol. That would make it a more popular and accepted part of everyday life.

Lexaria’s patented technology could be invaluable for companies catering to this desire. Its lipophilic enhancement technology is designed to improve the biological conductivity of active compounds, including those found in cannabis. It increases their potential for absorption by the body, meaning that consumers get better value for their cannabis. It also improves the taste, which will be important in making cannabis food and drinks popular. Recent tests have shown good results for applying this technique to active ingredients derived from cannabis.

Lexaria plans on licensing this technology to third-party partners and was recently awarded its 9th and 10th granted patents applicable for cannabis beverages. With cannabis-infused food and drink set to hit the Canadian market next year, and with large companies eyeing its potential, plenty of companies are sure to be interested in such technology that takes advantage of Lexaria’s leadership position.

Growing with the Market

The legalization of recreational cannabis is good for companies already working in the Canadian medical market such as Tilray, Inc. (NASDAQ: TLRY). A company with a strong pedigree in research and development, Tilray is expanding its sales potential in preparation for the recreational market. Its High Park Farms subsidiary recently received a license to sell cannabis in Canada and has already carried out several harvests to get stocks ready for sale. Such moves have led to positive views of the company’s future, with Wall Street commentators predicting a huge rise in the value of its shares over the next year.

The expectation of huge growth in the cannabis industry is helping companies raise extra finance to tap into that market. GW Pharmaceuticals Plc (NASDAQ: GWPH) has just raised over $345 million through a public offering. A medical cannabis company, GW isn’t currently involved in the recreational sector but is still profiting from the growth it brings.

One of the big players in Canada’s medical cannabis market, Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB), has been laying the groundwork to make the most of recreational sales. The company has supply agreements with provinces across Canada, giving it the opportunity to reach a broad customer base. As well as providing quick profits, this will help to establish brand recognition early on for greater influence as the market grows.

While attention is currently focused on Canada, that is just one part of the cannabis market. As with other industries, global reach will eventually decide the biggest players, and Cronos Group, Inc. (NASDAQ: CRON) (TSX: CRON) is already working on such expansion. With subsidiaries in North and South America, Europe, Australia and Israel, the company is tapping into growing cannabis markets around the world. Lessons from Canada will help in developing these other markets and in positioning Cronos to make the most of them.

The legalization of cannabis in Canada is a critical part in an international puzzle, one whose pieces include unexpected growth, global connections and transformations in consumer habits. Put together, these pieces offer the hope of a profitable future for cannabis companies.

For more information on Lexaria Bioscience Corp., visit Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Hemp and CBD Set to Eclipse the THC Marijuana Market

CannabisNewsWire Editorial Coverage: As the cannabis market continues to grow, hemp and cannabidiol (CBD) are occupying an increasingly large share of the escalating industry.

Hemp, the form of cannabis without psychoactive tetrahydrocannabinol (THC), is an important part of the cannabis market.
Hemp is common in many health and wellness products.
Total sales of hemp-derived products are expected to exceed $1 billion this year.
Some industry experts expect hemp products to soon exceed marijuana for their share of the cannabis industry.

Sugarmade, Inc. (OTCQB: SGMD) (SGMD Profile) is taking advantage of this shift by making a heavy investment in hemp production. Medical marijuana company Tilray, Inc. (NASDAQ: TLRY) bridges the gap between product types through its production of CBD oils. One of the largest cannabis growers in Canada, Canopy Growth Corp. (NYSE: CGC) provides plants used in a wide range of products. GW Pharmaceuticals Plc (NASDAQ: GWPH) has created the first cannabis-derived prescription drug approved by the U.S. Food and Drug Administration. Meanwhile, public acceptance and more positive perception of the cannabis sector are shifting, thanks at least in part to publicity efforts by shifted by cannabis companies such as Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB).

To view an infographic of this editorial, click here.

The Two Sides of the Cannabis Market

It’s all too easy to view the cannabis sector as a single market providing variations on the same product. In reality, it’s an increasingly complex and varied industry. Its primary plants and products can be divided into two groups: marijuana (and THC) in one category, and hemp (and CBD) in the other.

The marijuana piece of the cannabis market is the one more traditionally recognized. In this space, plants grown, cultivated and used contain THC, the psychoactive ingredient that gets drug users high. THC is the reason for cannabis’ ongoing popularity as a recreational drug worth hundreds of millions of dollars in both legal and illegal markets.

The other side of the market is centered around hemp. Hemp does not contain THC; rather it contains CBD, an active ingredient found in other cannabis plants. CBD has fueled the development of medical marijuana applications, but alternative products that utilize the substance are increasingly popular in the health and wellness markets, where they can be bought more widely than medical marijuana. As a result, some industry experts note that hemp may soon make up the larger part of the cannabis industry.

The Growth of the CBD Market

Though less well-known outside of specialist markets, CBD is becoming a more accessible way to benefit from cannabis. This has led to investment from companies across the cannabis sector, including Sugarmade, Inc. (OTCQB: SGMD).

Sales of hemp-based products in the United States reached $820 million last year, of which $190 million, or 23 percent of sales, consisted of CBD-derived products, according to Hemp Business Journal. That total for hemp is expected to pass a billion dollars this year.

Predictions for the future are even more promising. The same Hemp Business Journal article estimates that the hemp market will reach $1.9 billion in the United State by 2022, with $646 million of that coming from CBD and its derivatives. The Brightfield Group is even more optimistic in its assessment. The group’s industry specialists believe that CBD could outstrip the rest of the cannabis sector in size in the next few years.

For companies such as Sugarmade, whose business is closely tied to CBD, these developments create opportunities for expansion and innovation.

CBD Enters the Mainstream

A wide variety of end-use product potential is helping hemp gain mainstream use and acceptance. This market includes supplements, personal care products, textiles, and food and industrial applications, as well as CBD and the support services provided Sugarmade and other similar companies.

The hemp market has grown 15 percent per year over the past few years. Unlike marijuana sales, this growth isn’t driven by the medical and recreational sectors. Instead, body products and supplements have been key factors. Much of the hemp for these products has been imported from Canada and China, with imports totaling $78.2 million in 2015, not counting textiles, paper products or construction materials.

The hemp market is expected to be strengthened by the2018 Farm Bill currently making its way through the U.S. Senate. Legislation included in the act, supported by the Senate majority leader, would remove industrial hemp from the Controlled Substances Act, making it easier for farmers to grow hemp for CBD and other agricultural purposes. Since the last farm bill was passed four years ago, some farmers have been able to legally set up test production of hemp for CBD, but widespread cultivation has not been permitted.

The extent of the change permitted by the expected agricultural law remains uncertain. Other issues unrelated to cannabis are currently holding up the Farm Bill, despite widespread bipartisan support for the hemp provisions. Once the bill passes, the impact for CBD will also depend upon decisions made by state authorities and the FDA. But the bill will certainly ease the way for potential hemp growers in states that support the CBD industry. Until now, national law only allowed the growing of hemp and harvest of CBD in state pilot programs and for academic research; in the 2018 Farm Bill, those limitations are eliminated.

Clearly, The legalization of hemp and CBD on the federal level will only benefit companies such as Sugarmade. Previously, access to financial and support services could be difficult for companies working in the cannabis sector. Marijuana retailers had to resort to cash payments or newly developed electronic systems because banks feared doing business with companies defying federal law. Making hemp legal will allow a wide variety of support systems to evolve.

Innovating with CBD

The success of companies such as Sugarmade that are working in the CBD space comes in large part through innovation. These companies recognize the need to research, offer, and implement new products, services and investments to drive growth.

New products will take CBD into new commercial categories. Hemp-derived beverages and pet foods are both on the horizon. Medicines are being tested. Paper, cloth and construction are also industries that stand to benefit from additional hemp offerings.

Sugarmade’s success comes through expansion in hydroponics, the company’s entry into the cannabis space. Hydroponic equipment is key to cultivating cannabis and, as a result, hydroponic companies have seen substantial growth over the past few years. Sugarmade is building upon its existing growth by acquiring two other hydroponics companies, a move that turned the company into one of the leading players in hydroponics. This move is also expected to raise Sugarmade’s revenues next year from $30 million to $75 million as the market for hemp and its support services grows.

Sugarmade has also reinforced its position in the market through more direct investment in CBD. The company recently committed to investing a million dollars in Hempistry, Inc. The investment is targeted to support Hempistry’s work on an ultra-high CBD-content hemp strain being grown in Kentucky. It also positions Sugarmade to profit directly from the staggering growth in CBD.

The impact of the hemp industry extends beyond the United States. Sugarmade has made moves into Europe as well, selling hydroponics in the United Kingdom. While the current hemp market in Europe is small, savvy companies are evaluating opportunities to get in now. Where America leads, Europe is likely to follow, which means the road towards legalized cannabis and a thriving CBD market may be imminent.

Cannabis Competitors

A number of companies are competing for a share of the CBD market.

For medical marijuana company Tilray, Inc. (NASDAQ: TLRY), CBD is a natural extension of its other work. The company has developed CBD oil for medical use and is one of the first to sell such a product into the United Kingdom after top politicians intervened to make CBD available for treating rare childhood forms of epilepsy. A strong program of research and development has led to growth for the company, which is now making initial public offerings in the United States and Canada to finance further work.

Canopy Growth Corporation (NYSE: CGC) is one of the largest cannabis companies in Canada, a leading market for cannabis and CBD. With 5.6 million square feet of growing space spread across its facilities and subsidiaries, three-quarters of it licensed by Canadian authorities to grow cannabis, Canopy Growth has become a powerhouse within the industry and is breaking new ground for cannabis companies, having completed the first legal transfer of cannabis from Canada to the United States using a DEA-issued permit. This transfer, for medical research purposes, seems to reflect a softening of DEA attitudes as the agency adjusts to the changing status quo.

Medical cannabis research is also important to GW Pharmaceuticals Plc (NASDAQ: GWPH). The company created the first cannabis-based prescription medicine to gain FDA approval and continues to innovate through its research and product divisions. Like Tilray, the company is committed to growth, having recently announced new shares to raise $300 million of finance.

Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB) isn’t just selling its own CBD-rich health and wellness products — it’s also working to raise the public profile of the cannabis industry. It has partnered with Elevate, the annual citywide Toronto festival, to create tracks discussing cannabis and health issues. These events will encourage discussion about the health potential of CBD and marijuana, as both sides of the industry continue to gain in size and public recognition.

The cannabis industry has seen huge growth over the past decade, and now it’s going through big changes. Commercial CBD and hemp, until recently existing in the shadow of medical cannabis and recreational marijuana, could soon be the leading products in a growing global market.

For more information on Sugarmade, visit Sugarmade, Inc. (OTCQB: SGMD)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Fresh Acquisitions Help Companies Profit from Growth in the Cannabis Sector

CannabisNewsWire Editorial Coverage: A wave of acquisitions is sweeping the cannabis sector, as increasing legalization draws the attention of big business.

Large and mid-tier cannabis companies are absorbing their smaller competitors.
Tobacco and alcohol companies are moving in as a natural extension of their current ranges.
This is supported by growth not just among cannabis growers but also for businesses supporting them.

Cultivation supplies company Sugarmade, Inc. (OTC: SGMD) (SGMD Profile) has recently announced the acquisition of hydroponic product companies that could more than double its revenue. Tilray, Inc. (NASDAQ: TLRY) is fueling expansion through an initial public offering as it begins its first sales of CBD oil products in the United Kingdom. Drinks giant Constellation Brands now owns a large chunk of Canopy Growth Corp. (NYSE: CGC), one of Canada’s largest cannabis companies. GW Pharmaceuticals Plc (NASDAQ: GWPH) is releasing fresh shares to fund its R&D-driven growth. Meanwhile, Aurora Cannabis, Inc. (OTCQX: ACBFF) is making acquisitions across the Atlantic, buying out a pair of European hemp companies.

To view an infographic of this editorial, click here.

Acquisitions Grow in Cannabis Sector

Twenty years ago, it would have sounded like a science fiction fever dream, but today the cannabis industry is one of the fastest-growing sectors in the North American economy. The nine U.S. states where recreational cannabis is legal are about to be joined by the entire country of Canada, while another 20 states have legal markets for medical marijuana. Businesses catering to these markets are going from strength to strength, whether selling cannabis, manufacturing products derived from it or providing the tools and support that growers need.

This has led to a flurry of mergers and acquisitions in the cannabis sector. At the top end, large companies from other sectors have started buying into cannabis. Beverage manufacturer Constellation Brands owns more than a third of the shares in Canopy Growth, Molson is working with Hydropothecary, and Phillip Morris has been talking about moving into the sector. Seeing another legal drug coming into play, tobacco and alcohol companies want to buy their part of the future.

And there’s also been a lot of movement within the industry.

Cannabis Companies Buy Up Competitors

Among existing cannabis companies, consolidation is the name of the game. A wide scatter of small companies — startups created within a new and uncertain industry — are combining into larger operations.

One example is a recent series of acquisitions by Sugarmade, Inc. (OTC: SGMD). A Los Angeles company with warehouses in southern California, Sugarmade isn’t a purely cannabis-oriented business, but its work in restaurant supplies and packaging is increasingly taking a back seat. Its higher profile work is in the cannabis sector, where it provides cultivation supplies.

Sugarmade isn’t one of the big players in cannabis, but it has made bold moves for a mid-tier company. Following an SEC filing earlier this year, the company has recently made formal proposals for the acquisition of two hydroponic supply companies catering to the cannabis sector. These acquisitions would more than double Sugarmade’s expected revenue for next year, from $30 million to $75 million.

Even within the cannabis industry, this is an unusual move. Most of the mergers and acquisitions are being led by big companies, who can obtain external investment to drive their expansion. It’s a familiar case of success breeding success, as the largest companies are most able to grow. But Sugarmade is bucking that trend in a move that could see it join the big players, disrupting the status quo of the cannabis industry.

“These acquisitions will not only very significantly boost our top line revenue growth, but will also expand our distribution across the most important sectors of the fast-growing cannabis marketplace,” said Sugarmade CEO Jimmy Chan. “In addition to the revenue growth opportunities, we will also be afforded very meaningful cost savings across many operational functions. In particular, we believe there are strong cost synergies relative to manufacturing, purchasing, international transport, warehousing and shipment to customers. Perhaps most exciting, however, is that these acquisitions will place us among the largest public companies in the booming cannabis sector.”

It’s a strategy that brings a lot of obvious advantages. Greater integration smooths out supply chains and increases efficiency, reducing overheads to improve profits. It increases a company’s ability to bring specialist expertise in house. It increases a company’s influence in negotiating with suppliers and customers, as well as in lobbying authorities.

But in a sector where mergers are likely to continue, it also has another effect. As the big players in tobacco and alcohol look for cannabis businesses to buy, Sugarmade’s growing strength improves its bargaining position. Whether the company aims to be bought up or to hold onto its independence, it will be better able to negotiate from a place of strength.

Supporting Services

Talk about the cannabis industry usually focuses on the cultivators and distributors, those directly dealing with cannabis. But over the past decade, the industry has grown far more diverse. Support companies such as Sugarmade play an increasingly important role.

The most obvious support services are those supplying cultivation equipment. This is where Sugarmade’s main business lies, selling growers the tools they need to produce their crops.

Hydroponics, the growth of plants in water-based nutrients instead of soil, is an important part of this. Used to grow high-quality plants in indoor facilities, this method is central to the cultivation of controlled, high-quality cannabis crops in secure conditions. Hydroponic sales have allowed Sugarmade to expand beyond North America and into the European market, where cannabis is still largely illegal but its cultivation tools have other uses. The companies Sugarmade is buying also work in hydroponics and their acquisition could make the company a major player within that market.

Support services for cannabis are increasingly diverse. Equipment for waste disposal, lighting and growing beds are all important. Some of this is provided by hydroponics companies, while other components are created by specialist firms. Seeds are nurtured and sold, new plant strains grown, and growing and harvesting techniques developed. Research and financial services specifically geared toward cannabis add to a complex and multifaceted industry.

The Potential for Growth

Much as its opponents might disagree, the cannabis industry isn’t going away. In the United States, where Sugarmade is based, the industry shows every sign of continuing its rapid growth.

The biggest driver for growth is still legal change. The legalization of both medical and recreational cannabis has been spreading state by state, as increasingly liberal attitudes are reflected in the law. Though cannabis remains illegal at the federal level, the government has done nothing to clamp down on these efforts by states. If anything, the government’s attitude is softening, with this year’s Farm Bill set to legalize industrial hemp, a nonpsychoactive form of cannabis.

Industrial hemp is already being grown in test projects in the United States, creating impressive profits for the farmers involved. While its cultivation often operates differently from that of medical and recreational cannabis, it relies on much of the same knowledge and many of the same tools. For companies such as Sugarmade, which provide cultivation supplies, industrial hemp will mean significant opportunities for growth.

On top of this, there’s the long-term growth expected from cannabis companies within the states that have legalized their products. As the legal consumer market settles in, the habits of cannabis consumers will change. They’ll move away from buying from criminals, undermining illegal networks and giving more business to the legal companies. As these companies expand production facilities, the need for additional equipment and supplies will increase – supplies that can be provided by Sugarmade and the companies that it’s absorbing.

Many North American cannabis companies are seeing substantial growth. Tilray, Inc. (NASDAQ: TLRY) is looking to finance its ongoing expansion through initial public offerings in the United States and in Canadian provinces. A leading medical marijuana company, Tilray has sold its products to customers on five continents and is one of the first companies to sell CBD oil, a cannabis derivative, in the United Kingdom. Its expansion is driven not by acquisitions but by a strong research and development program.

Canopy Growth Corporation (NYSE: CGC) is one of the largest cannabis companies in Canada. Drinks manufacturer Constellation Brands has pumped over $4 billion into Canopy Growth, and the American giant now owns more than a third of Canopy Growth’s shares. It’s a move that will help the companies to collaborate in producing cannabis-infused drinks, which will become legal in Canada next year. More than this, it’s a move by a drinks manufacturer to get a foothold in cannabis and so expand from alcohol into another legal drug.

GW Pharmaceuticals Plc (NASDAQ: GWPH) has been growing through new products and research, with the creation of the first FDA-approved prescription medicine derived from cannabis plants. It has just announced the release of new shares, which are expected to raise $300 million in support of the company’s ongoing growth.

Aurora Cannabis, Inc. (OTCQX: ACBFF) is going international with its latest acquisition. In September, the company acquired Europe’s largest producer of organic hemp, Agropro UAB, and hemp processor and distributor Borela UAB. This will increase the company’s production of hemp-derived health and wellness products around the world.

With the cannabis industry expanding, mergers and acquisitions are helping to drive a round of growth, creating companies with the power to compete on the global stage.

For more information on Sugarmade, visit Sugarmade, Inc. (OTCQB: SGMD)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Public Acceptance Fuels Growth of CBD and Support Industries

CannabisNewsWire Editorial Coverage: Growing public acceptance of medical marijuana is having secondary effects on other industries.

Products using cannabidiol (CBD) are increasingly popular in areas such as wellness and cosmetics.
Hemp production is growing, with experimental projects improving cannabis cultivation techniques.
Services needed to support these markets, such as payment systems, are growing.

Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is benefiting from this in many ways, having invested in hemp, CBD products, rentable cultivation space and payment systems. Tilray, Inc. (NASDAQ: TLRY) is producing CBD oils and has become one of the first companies to sell these for medical use in the United Kingdom. Canopy Growth Corporation (NYSE: CGC) has received a massive investment from a drinks company, with the aim of producing CBD-infused drinks. GW Pharmaceuticals Plc (NASDAQ: GWPH) created the first prescription medicine derived from cannabis plants to receive U.S. Food and Drug Administration approval and is now heavily involved in research into using CBD to tackle epilepsy. Such drugs may also become useful for fighting insomnia, the subject of a new study by Cronos Group, Inc. (NASDAQ: CRON).

To view an infographic of this editorial, click here.

Public Acceptance of Medical Marijuana Growing

Attitudes towards cannabis and industrial hemp have shifted significantly in the United States in recent years, reflected by legal changes at the state level. The majority of states have legalized these substances for medical use, and a significant proportion now allow their sale for recreational purposes. Increasing access and legitimacy have encouraged an already existing trend toward more liberal views. As a result, 74 percent of Americans now support legislation that would protect states from federal prosecution for legalizing the drug.

Most tellingly, major companies are looking to tap into the popularity of industrial hemp. Coca-Cola, not a company known for taking great risks, is in talks with a major grower about a potential collaboration. This would involve producing drinks infused with cannabidiol (CBD), a non-psychoactive chemical found in industrial hemp. A growing body of research into CBD’s potential to relieve pain means that it is an increasingly popular part of the industry. As recreational marijuana use is legalized in Canada this month, companies such as Coca-Cola will use that country to develop and market test products that may later be sold in the United States.

Turning Public Approval into Profits

Reports about this shift in attitudes provide inherently useful information for politicians and public health officials. But for businesses such as Marijuana Company of America (OTC: MCOA), this information only becomes useful if they can turn it into profit.

MCOA is doing this by diversifying its activities and expanding upon existing work to strengthen its position within the market. The industry is now about much more than just growing and selling cannabis. It covers industrial hemp, plant processing, support services, technology and a wide range of products, some a long way from the smokable plants many people picture when they hear the word hemp.

The part of MCOA’s work that most obviously benefits from changing attitudes is its hempSMART line of products. These timely products are infused with hemp-derived CBD, the same chemical Coca-Cola is considering putting into drinks. But while it isn’t yet producing beverages, MCOA has found a wide variety of other ways to use CBD.

Most of the hempSMART brand is targeted at the wellness market. Products such as the recently relaunched hempSMART Brain are formulated to improve the well-being of consumers, in hempSMART Brain’s case by helping maintain mental clarity, alertness, focus and concentration. HempSMART has also entered the cosmetic and skin care realm with its hempSMART Face, a CBD facial moisturizer, which aims to refresh, replenish, and restore skin providing long-lasting hydration and balance.

The production and marketing of these products is made easier by the shift in public perceptions of industrial hemp. As it becomes more accepted, even consumers who aren’t interested in the substance itself are sometimes willing to try ancillary products.

Harvesting Hemp

For centuries, hemp was grown as a source of fiber. A plant related to marijuana but without its psychoactive properties, hemp is now seeing a revival, thanks to legal changes in both Canada and the United States.

In a joint venture with Global Hemp Group, Inc., MCOA has set up two separate hemp production projects — one in Oregon and the other in New Brunswick.

The purposes of these projects include increasing understanding of hemp, developing better cultivation methods, and creating improved strains. Staff at both sites are carrying out research, with support from the local government at the Canadian site. This work covers a range of issues important to hemp cultivation, including pest control and improving soil quality. Drones are used to oversee progress in New Brunswick, giving the company a good overview of how crops are progressing.

By gathering data on plants and cultivation methods, MCOA and Global Hemp are giving themselves an important advantage in a growing industry. Hemp fibers can be used to produce cloth and rope, adapting a historically popular use to the modern world. Perhaps more valuable financially, CBD oil can be extracted from the plants, providing biomass for the market. Growing strains with rich CBD content is an important part of the work at the Oregon site, work that could give the companies an edge over their competitors in the strains they grow.

The work on these sites is providing plenty of practical insights and experience, sometimes in unexpected ways. A bean harvester was recently used to harvest crops in New Brunswick, maximizing profits despite higher than normal weed growth. Experts such as Anthony Rushford, who has brought 20 years of experience in hemp breeding and genetics to the Oregon project — have also been recruited to provide insight on relevant issues.

Support Services

The growth of the marijuana, hemp and CBD markets has led to a need for support services. By expanding into these services, MCOA is further strengthening its position.

The company’s significant investment in MoneyTrac Technology represents a similar step toward diversification. MoneyTrac is a pioneer in alternative banking and electronic finance systems, using blockchain technology to power an accessible payment service. This can be accessed anywhere in the world and used by sellers to track their business and ensure legal compliance, as well as to easily take electronic payments.

As the industry grows, it will need technological solutions for the challenges it faces, and MoneyTrac provides one of those solutions. This technology has potential use beyond the cannabis market as a payment system for other under-served businesses. Both business practices and technology are changing as companies adapt to the emerging commercial environment in the United States.

The Commercial Power of Marijuana Derivatives

The growing acceptance of medical marijuana is providing impetus for many businesses within the sector that are exploring the other products these plants can provide.

Tilray, Inc. (NASDAQ: TLRY), a leading medical marijuana company, sells cannabis flowers and extracts to patients and medical providers on five continents. With a strong investment in research and development, Tilray has been creating other products derived from these plants, including a range of CBD oils. As a result, it is one of the first companies to sell CBD oil into the United Kingdom following a high profile legal change that allowed British patients access to these oils for the first time.

Canopy Growth Corporation (NYSE: CGC) is already one of the leading marijuana companies working in Canada, one with extensive deals to make use of that country’s growing market. Canopy Growth has received a significant financial and publicity boost thanks to a recently approved $4 billion investment from American drinks giant Constellation Brands. This collaboration between the two companies is expected to lead to CBD-infused drinks, another innovation within the industry.

A company with 20 years’ experience developing cannabinoid treatments, GW Pharmaceuticals Plc (NASDAQ: GWPH) created the first prescription medicine derived from cannabis plants to be approved by the U.S. Food and Drug Administration. GW Pharma has been carrying out research on the use of CBD in tackling rare and dangerous forms of childhood epilepsy, and recently presented data on this work to the 13th Annual European Congress of Epileptology. This research is creating greater support for the safety and effectiveness of CBD in dealing with these diseases.

Research is widening the number of ways in which cannabis and cannabis-derived products can be used. Cronos Group Inc. (NASDAQ: CRON) recently announced a study to research the use of cannabis in tackling insomnia.

A diversity of products and uses is allowing marijuana companies to grow in strength, providing support services, medicines, research and rented cultivation facilities alongside their core products of cannabis and CBD oils. It’s a path that can only strengthen the industry.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector

CannabisNewsWire Editorial Coverage: Intangible assets such as patents increasingly dominate the global business landscape, especially in the pharmaceutical sector.

Intangible assets are estimated to be worth trillions of dollars in the United States alone.
These assets drive deals as companies acquire smaller patent holders.
In growing sectors such as cannabis, smaller companies are rushing to establish intangible assets ready for expected market growth.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) is one of the leaders in the world of cannabis, with applications made for more than 50 different patents and more to come. Tilray Inc. (NASDAQ: TLRY) is also focusing on building its intellectual property (IP) portfolio, including exclusive rights to at least 22 issued or pending patents. In wake of receiving FDA approval of its Epidiolex® (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, GW Pharmaceuticals Plc (NASDAQ: GWPH) has applied for five new Epidiolex patents. Recently Canopy Growth Corporation (NYSE: CGC) announced that it has, alone or with its subsidiary or joint-venture partners, filed eight provisional U.S. patents pertaining to the delivery and application of cannabis and cannabinoid-based therapeutics. And through its ownership of CanniMed, Aurora Cannabis, Inc. (OTCQX: ACBFF) has obtained six patents related to cannabinoid delivery for pain management.

To view an infographic of this editorial, click here.

The Power of Intellectual Property

Intellectual property is now one of the most important parts of the global economy. Copyrights, trademarks and patents are a vital weapon in the arsenal of many businesses. For some companies, this is a secondary consideration, a way to strengthen and protect their positions within their fields. For others, it’s their entire focus — a way to dominate a sector or provide valuable returns.

The power of IP means that no part of the economy goes untouched. New industries often arise off the back of new IP. Even when that’s not the case, the development of new techniques and technologies frequently lead to the creation of patents, as companies work to innovate and control techniques that give them an edge over their competitors. For relatively new sectors, such as the cannabis market, this means the sudden flourishing of IP and a race by companies to stake their claim on these valuable assets. As a sector matures, so will its IP market.

The Value of Intangible Assets

Patents are a big part of business for companies such as Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), for whom developing and protecting new technology is fundamental to success. Whether it’s underlying technology such as DehydraTECH, the company’s system for increasing the body’s absorption of chemical compounds, or specific products derived from DehydraTECH, such as TurboCBD, Lexaria’s success is founded on its distinctive IP.

IP is part of a wider sector of the economy — intangible assets. This is the wealth provided not by physical assets and the processes that directly transform them but by less visible, more abstract resources. It includes IP, whose value is often examined and measured, as well as harder-to-pin-down elements such as business processes and reputation.

These factors have always played a part in business, but their growing recognition and analysis has led to the growth of companies whose main focus is on intangible assets, from investment research firms and reinsurers to patent licensing and enforcement companies.

Representing around a third of the U.S. economy, intangible assets are now consciously analyzed and developed by virtually every business, even if they don’t recognize the “intangible asset” label. Companies with a solid focus on these areas can place themselves in positions of great strength.

Patents in a New Sector

The speed at which intangible assets can develop is well illustrated by movements in the cannabis sector, where many of Lexaria’s patents apply.

The legal global cannabis market started to emerge only recently, thanks to a handful of countries allowing medical marijuana. The market has started to mature through a small but growing number of territories with legal markets for recreational cannabis, as well as the separate management and licensing of industrial hemp. Legal cannabis is now a multibillion-dollar business. Although Lexaria’s technology has other profound drug delivery applications, cannabis is where it looks set to have the most immediate impact.

This has led to a rush to control intangible assets around cannabis. It’s noteworthy that Chinese companies own more than half of the cannabis-related patents registered with the World Intellectual Property Organization, even though the cannabis trade remains illegal in China. China has a good eye for long-term developments and is setting itself up to control a growing global trade.

Outside of China, Lexaria is one of the world’s biggest holders of cannabis patents with eight patents already granted. The company currently holds four patents in the United States and four in Australia, covering aspects of its work to make beneficial drugs more palatable and effective. In addition, the company has further patent applications in process in more than 40 countries as part of a concerted strategy to expand its patent portfolio. This is made possible by the focused, tangible research and development being carried out by the company and is ultimately driven by the need to develop and control intangible assets.

Lexaria has disclosed it expects four more patents to be granted in 2018, bringing its total to twelve. Of note, all twelve of these are within a single patent family — and Lexaria expects patent success across all nine families of its current applications. Indeed the company recently revealed that it has seven more patent families in the works. Lexaria’s goal is to have some 200 patents pending or granted which, if achieved, could turn the organization into an IP behemoth in the global cannabis industry.

The Value of Patents

The commercial value of patents, even those still pending approval, can be extraordinary, reaching billions of dollars. In 2011, Nortel sold 6,000 patents and patent applications for $4.5 billion. The following year, AOL sold 925 patents to Microsoft for more than a billion dollars. While some companies develop patents purely to protect their work, others develop them specifically to be sold.

This focus on intangible assets drives many mergers and acquisitions. The Craftsy digital network developed online shows such as “Man about Cake” with a focus on audience rather than immediate profit, leading to the company’s acquisition by NBC Universal. The intangible assets of the company’s identity, reputation and audience had become highly valuable in themselves.

Similar priorities can be seen on a far larger scale in SoftBank’s $31.4 billion acquisition of chip designer ARM Holdings, or roughly $7 million per patent or patent application. ARM’s revenues were only $1.5 billion per year, but its 4,500 patents cover technology of potentially incredible value. In just three years, the desire to control patented drugs and processes in the healthcare sector overall resulted in 58 mergers and acquisitions with values of a billion dollars or more.

In Lexaria’s field of pharmaceuticals, patents are crucial, representing both the outcome of years of R&D and also potential market share and control in the emerging global cannabis business. Lexaria is attempting to own enough IP in the global cannabis industry that patent royalty revenues begin to flow worldwide.

Because patents are among the most valuable assets a company can own, a small investment in research now may pay off in a huge way in years to come. In a sector with such huge growth potential as cannabis, Lexaria’s IP portfolio may generate cash flows regardless of whether other companies intend to license the technology or not; by owning core IP, other companies may be forced to pay royalties. If Lexaria’s goal of owning hundreds of issued patents becomes a reality, the company’s patent portfolio could have huge ramifications on its valuation.

Powered by Intellectual Property

Lexaria isn’t alone in its commitment to strengthen its IP collateral. Tilray Inc. (NASDAQ: TLRY) is also focusing on building its IP portfolio including exclusive rights to at least 22 issued or pending patents. Tilray CEO Brendan Kennedy has observed that if cannabis companies are going to move forward, they’ll need to develop IP in both the medicinal and recreation aspects of the cannabis spectrum.

GW Pharmaceuticals Plc (NASDAQ: GWPH) has established a leading position in the development of plant-derived cannabinoid therapeutics through its intellectual property portfolio, proven drug discovery and development processes, and regulatory and manufacturing expertise. The company successfully developed the world’s first prescription medicine derived from the cannabis plant.

In addition to the eight provisional patents it has filed, Canopy Growth Corporation (NYSE: CGC) has updated applications relating to earlier insomnia patent applications, bringing its total number of U.S. provisional patent filings to 39. The filings are part of a concerted plan by Canopy Growth to deliver to patients and healthcare providers innovative medicines and health products targeting disease areas with substantial medical needs.

Aurora Cannabis, Inc.’s (OTCQX: ACBFF) pain-management patents are only part of the company’s commitment to creating a stronghold in the cannabis market. Aurora has become one of the fastest-growing cannabis companies, as evidenced by Aurora Sky, the company’s 800,000-square-foot flagship facility; by launching the world’s only mobile app for ordering medically prescribed cannabis; and by being the only LP to service two metropolitan areas with same-day delivery.

With so much value placed on intangible assets, patents are fueling growth and acquisitions worth billions of dollars. In the pharmaceutical sector and beyond, patents definitely appear to be where the big money is.

For more information on Lexaria Bioscience Corp., visit Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

About CannabisNewsWire

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.